Last 12 months
Inside the activity.
0 purchase rows · 57 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 16 |
| Dec 2025 | 0 | 12 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 9 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 4,979 | $35.17 | $175,112.43 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,887 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $34.95 to $35.27. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 2,595 | $34.39 | $89,251.39 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,866 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $33.93 to $34.93. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 1,507 | $33.28 | $50,151.45 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,461 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $32.92 to $33.68. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 3,750 | $20.21 | $75,787.50 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:38 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 21:00 UTC |
Holstein JensDirector
|
PurchaseCommon Stock | 2,000 | $35.19 | $70,389.20 |
DisclosureSEC source: 0001384101-21-000098 · wf-form4_162284040266451.xml · nonDerivative · entry 1 Holstein Jens · CIK 0001819880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: Represents weighted average purchase price. Purchase prices for the transactions range from $35.15 to $35.40. Detailed information regarding the number of shares purchased at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:56 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 912 | $36.07 | $32,895.84 |
DisclosureSEC source: 0001384101-21-000096 · wf-form4_162284014712611.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,812 F1 · kind: The reporting person is reporting the withholding of 292, 248 and 372 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587, 500 and 750 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:53 UTC |
Anderson Bonnie HDirector · Executive Chairwoman
|
Tax withholdingCommon Stock | 2,288 | $36.07 | $82,528.16 |
DisclosureSEC source: 0001384101-21-000094 · wf-form4_162283995384640.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,725 F1 · kind: The reporting person is reporting the withholding of 738, 738 and 812 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875, 1,875 and 2,062 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:02 UTC |
Stapley MarcChief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 138,051 | $0.00 Strike: $36.60 | $0.00 |
DisclosureSEC source: 0001384101-21-000092 · wf-form4_162275411446342.xml · derivative · entry 2 Stapley Marc · CIK 0001539796 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,051 Underlying: Common Stock · 138,051 shares Expires 2031-06-01 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on June 1, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:02 UTC |
Stapley MarcChief Executive Officer
|
GrantCommon Stock | 46,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000092 · wf-form4_162275411446342.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,807 F1 · kind: Restricted stock units awarded on June 1, 2021 vest 25% on June 2, 2022 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:45 UTC |
Alley Beverly JaneVP, Corporate Controller
|
GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000084 · wf-form4_162137063577276.xml · nonDerivative · entry 1 Alley Beverly Jane · CIK 0001543892 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · kind: Restricted stock units awarded on May 17, 2021 vest on May 15, 2022 subject to the continuing employment of the Reporting Person through such date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:34 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 14,065 | $0.00 Strike: $5.61 | $0.00 |
DisclosureSEC source: 0001384101-21-000087 · wf-form4_162145643157642.xml · derivative · entry 3 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,117 Underlying: Common Stock · 14,065 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:34 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 14,065 | $5.61 | $78,904.65 |
DisclosureSEC source: 0001384101-21-000087 · wf-form4_162145643157642.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:41 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 250 | $50.03 | $12,507.00 |
DisclosureSEC source: 0001384101-21-000074 · wf-form4_162024723253740.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 8,800 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.92 to $50.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:41 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 650 | $49.00 | $31,849.03 |
DisclosureSEC source: 0001384101-21-000074 · wf-form4_162024723253740.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 9,050 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.55 to $49.22. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:41 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 3,527 | $48.01 | $169,343.61 |
DisclosureSEC source: 0001384101-21-000074 · wf-form4_162024723253740.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 9,700 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.54 to $48.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:04 UTC |
Alley Beverly JaneVP, Corporate Controller
|
GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $52.72 | $0.00 |
DisclosureSEC source: 0001384101-21-000061 · wf-form4_161765657973864.xml · derivative · entry 1 Alley Beverly Jane · CIK 0001543892 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on April 1, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 20:48 UTC |
Bhanji MunaDirector
|
GrantCommon Stock | 11,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000055 · wf-form4_161653247749352.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,541 F1 · kind: Restricted stock units awarded on March 19, 2021 vest as to one-third (1/3) of the shares on each of the first, second and third annual anniversaries of the date of grant. F2 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 17 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 17,500 shares Expires 2030-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F14 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 16 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 3,750 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F13 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,407 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 15 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,625 Underlying: Common Stock · 4,407 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F12 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · derivative · entry 14 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,313 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F11 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 300 | $55.49 | $16,647.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 13 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,724 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F10 · price: Represents weighted average sales price. Sale prices for the transactions range from $55.31 to $55.67. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 1,431 | $54.72 | $78,310.04 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 12 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,024 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F9 · price: Represents weighted average sales price. Sale prices for the transactions range from $54.11 to $55.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 2,606 | $53.50 | $139,414.49 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 11 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,455 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F8 · price: Represents weighted average sales price. Sale prices for the transactions range from $52.99 to $53.99. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 5,032 | $52.38 | $263,564.08 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,061 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F7 · price: Represents weighted average sales price. Sale prices for the transactions range from $51.94 to $52.93. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 8,114 | $51.38 | $416,900.57 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,093 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F6 · price: Represents weighted average sales price. Sale prices for the transactions range from $50.90 to $51.89. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 2,819 | $50.40 | $142,073.37 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,207 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F5 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.87 to $50.87. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 2,991 | $49.22 | $147,209.84 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,026 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.82 to $49.81. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 8,483 | $48.29 | $409,607.59 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,017 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.80 to $48.80. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 20,239 | $47.11 | $953,544.29 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,500 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $46.78 to $47.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 17,500 | $24.69 | $432,075.00 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 3,750 | $20.21 | $75,787.50 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:33 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 5,313 | $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-21-000044 · wf-form4_161524279377824.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:13 UTC |
Ho MarkPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 490 | $62.15 | $30,453.50 |
DisclosureSEC source: 0001384101-21-000042 · wf-form4_161489598874283.xml · nonDerivative · entry 1 Ho Mark · CIK 0001554165 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,728 F1 · kind: The reporting person is reporting the withholding of 78, 103 and 309 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 188, 250 and 750 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 784 shares of common stock purchased on January 31, 2021 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:10 UTC |
Kennedy KeithCOO / CFO
|
Tax withholdingCommon Stock | 5,783 | $62.15 | $359,413.45 |
DisclosureSEC source: 0001384101-21-000040 · wf-form4_161489582980243.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,858 F1 · kind: The reporting person is reporting the withholding of 284, 220, 3,519, 440 and 1,320 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 644, 500, 8,000, 1,000 and 3,000 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019, February 28, 2019, July 1, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:05 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 5,995 | $62.15 | $372,589.25 |
DisclosureSEC source: 0001384101-21-000038 · wf-form4_161489554524867.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,769 F1 · kind: The reporting person is reporting the withholding of 292, 248, 3,967 and 1,488 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588, 500, 8,000 and 3,000 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019, February 28, 2019 and February 28, 2020 respectively, and does not represent a saleby the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:03 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 6,320 | $62.15 | $392,788.00 |
DisclosureSEC source: 0001384101-21-000036 · wf-form4_161489538807035.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,948 F1 · kind: The reporting person is reporting the withholding of 988, 988 and 4,344 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875, 1,875 and 8,250 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:15 UTC |
Erlinger III James HEVP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $58.06 | $0.00 |
DisclosureSEC source: 0001384101-21-000026 · wf-form4_161472328501095.xml · derivative · entry 2 Erlinger III James H · CIK 0001575957 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-02-26 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 26, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:15 UTC |
Erlinger III James HEVP, General Counsel
|
GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000026 · wf-form4_161472328501095.xml · nonDerivative · entry 1 Erlinger III James H · CIK 0001575957 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · kind: Restricted stock units awarded on February 26, 2021 vest 25% on March 2, 2022 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:23 UTC |
Kennedy KeithCOO / CFO
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $58.06 | $0.00 |
DisclosureSEC source: 0001384101-21-000030 · wf-form4_161472375502966.xml · derivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-02-26 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 26, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:23 UTC |
Kennedy KeithCOO / CFO
|
GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000030 · wf-form4_161472375502966.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,641 F1 · kind: Restricted stock units awarded on February 26, 2021 vest 25% on March 2, 2022 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:12 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $58.06 | $0.00 |
DisclosureSEC source: 0001384101-21-000024 · wf-form4_161472310232261.xml · derivative · entry 5 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-26 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 26, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:12 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000024 · wf-form4_161472310232261.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,268 F1 · kind: Restricted stock units awarded on February 26, 2021 vest 25% on March 2, 2022 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:19 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $58.06 | $0.00 |
DisclosureSEC source: 0001384101-21-000028 · wf-form4_161472354334446.xml · derivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-26 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 26, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:19 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000028 · wf-form4_161472354334446.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,764 F1 · kind: Restricted stock units awarded on February 26, 2021 vest 25% on March 2, 2022 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC |
EASTHAM KARINDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · derivative · entry 5 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 200 | $61.77 | $12,354.00 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · nonDerivative · entry 4 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 3,606 | $61.09 | $220,298.83 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $60.62 to $61.59. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.